Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib for recurrent thymoma
ChiCTR2000030243Phase 4Recruiting
- Sponsor
- People's Hospital of Shijiazhuang
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anlotinib in thymoma, sponsored by People's Hospital of Shijiazhuang. Primary endpoint: progression-free survival. Started Feb 2020; status: recruiting.
02
Drugs
anlotinib
03
Conditions
thymoma
Beyond the preview
Go deeper on ChiCTR2000030243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030243.